---
title: San Antonio Breast Cancer Symphosium
author: Package Build
date: '2025-12-10'
slug: []
categories:
  - Cancer
  - Genomics
  - Pathology
tags:
  - Pathology
subtitle: ''
summary: ''
authors: []
lastmod: '2025-12-10T12:41:48+09:00'
featured: false
draft: false
image:
  caption: ''
  focal_point: ''
  preview_only: false
projects: []
---



<div id="lobular-carcinoma" class="section level3">
<h3>Lobular carcinoma</h3>
<ul>
<li><p>Christos Sotitiou, Institue Jules Bordet</p></li>
<li><p>ILC tumor microenvironment &amp; PI3K inhibition (taselisib)</p>
<ul>
<li>ILC appears enriched in M2 macrophages with increased PI3K/AKT/mTOR signaling without pathway alterations.</li>
</ul></li>
<li><p>Higher M2/M1 ratio is associated with better <strong>taselisib</strong> response, <strong>independent of PIK3CA mutation status</strong>.</p></li>
<li><p>Lobular tumors show higher ORR with taselisib than placebo in both <strong>PIK3CA-mut</strong> and <strong>PIK3CA-wt</strong> subsets.</p></li>
<li><p>A proposed dual mechanism: inhibition of <strong>PI3Kα</strong> in tumor cells and <strong>PI3Kγ</strong> in macrophages, potentially driving macrophage repolarization and stronger anti-tumor immunity.</p></li>
<li><p>ILC4TME framework suggests four ILC subtypes (NSE, P, ARE, MIE) that may enable refined patient stratification.</p></li>
<li><p>Clinical context</p></li>
<li><p><strong>RX-PONDER</strong>: chemo benefit appears smallest around higher RS and increases as RS decreases, with greatest benefit at very low RS.</p></li>
<li><p><strong>Genomic risk</strong>: ILC and IDC show <strong>nearly identical outcomes</strong> when matched by genomic risk categories.</p></li>
</ul>
</div>
<div id="implications-for-next-ilc-specific-trials" class="section level3">
<h3>Implications for next ILC-specific trials</h3>
<ul>
<li>Prioritize mechanism-based treatment selection and resistance planning.</li>
<li>Use ILC-suitable assessments (e.g., WB-MRI, FES-PET, FAPI-PET, liquid biopsies).</li>
<li>Consider ILC-suitable endpoints (cellularity, ctDNA dynamics, long-term outcomes).</li>
<li>Ensure central pathology review; incorporate surgical endpoints.</li>
<li>Build multi-center/international recruitment networks.</li>
</ul>
</div>
